for you joining everyone. today. Monique, Thanks, morning, and good Thank us
we of programs. be on my exciting XXXX X:XX hold with weeks in York at updates as another are comments on year. detailed from only meeting, is be City New I to our going on give update pleased which more all X keep analyst here our our where are away March we p.m., will four brief we'll will progress. an to We
noted me for persistent program, our PH Approval I we where get preparing would newborn push for PMA submission we with Let and to to out hypertension three study resources submitted filing, earnings run last for were or ago, how On parallel. our begin months bronchiolitis are pivotal we pulmonary the need Premarket are U.S. PMA given our of our both our our call that to we LungFit unable or programs in allocating that PPHN. IDE
time, occur we resources I ability quarter weeks our am the XX in very we LungFit in week, pleased that focus LungFit best PMA Thus, submission to commercially fourth the our will our XXXX. this remain confident is to report to will calendar moving today. PH to PH system our on next that estimate At from XX submission. be approximately launch PMA in
terminate plans. We The our to breach. a decision to our With commercial exploring in launch. launch commercialization respect December of does termination options are currently Circassia agreement Pharmaceuticals change and for all announced our our with not Circassia we plans for launch, XXXX late with our material for partnership
on product U.S. in our launch own fully are We the prepared to the
several take cylinder-based discussions However, and safety for hundred the as advantages the ongoing partners U.S. ex-U.S. us our with the cost help market dollar significant for market. of Many a highlighted operational, share I commercial think million are systems U.S. potential have which times, well markets. over we will as systems, of
our PH He us team LungFit March Beyond has and Fatkin PH Commercial the with Day Chief Analyst Officer, displaying successfully forward plans looking and system. on Air and system to been months Our for launch to has X. the now experience Duncan are the LungFit discussing XX at the our
before in Israel the BRO XX% end the final complete enrollment of over bronchiolitis, patients month. pilot enrolled expect LungFit in program, a this for second of have study our to In we and
We this announce from in expect pilot study to May. data
Our clinical executing of the job trial. an done excellent on has team
our should XXXX, around of to with earlier, the track are completed pivotal trial midyear. on second The in pivotal study be we reported 'XX 'XX mentioned the in data winter I quarter As initiate United season States. in
As leading alone. a hospitalization is will are hydrogen. at X. our on worldwide to reminder, in our of annually launch approved More bronchiolitis, XXX,XXX March drugs Day a and be this product and the treatment discussed no cause Analyst bronchiolitis the over of the oxygen care is of for on infants hospitalizations U.S. with There currently plans for standard
RSV. by like would caused I point other of than is bronchiolitis viruses out to XX% that about
other these viruses Some coronavirus. are deemed of
the strain We the global monitoring are with coronavirus situation all from China.
on attempted has that confidence global treat in on test specific help system forward difficult-to-treat have certain we BRO to types coronavirus alarm it never our of that system our look data opportunity LungFit our we causing While to the the as current currently on already we the will effective the it based is view China. coronavirus from company And responsibility generated. chance coronavirus is the to We test can. to the We coronavirus treating get a to if strains. hopefully,
dubbed year LungFit program, patients our multi-centered, NTM by infection study to our a pilot In lung self-administered, XX-week, NTM are XXXX. with planning initiate in mid-calendar program at-home we at-home or better
parts this will diagnosed called avium are to will may be study we abscessus also complex preclinical Patients abscessus to Patients on data that Based million up nitric known complex be at-home Mycobacterium as MAC. an the or Mycobacterium confident XXX oxide. per and titrated generated clinical succeed. pilot of date, a or with either
home patients self-administer We are the of our the encouraged simplicity system by NTM LungFit themselves. the in
bacteria quality is life it straightforward function The to power in plug on has into with XX system. the as infected mask the improved physical the of insert of well physical It's and study For The safety the profile bacteria. designed system, place versus any the XX-week and as on success face emphasized either with a FDA of button. solely the simple eradication study breathing switch function and patients turn removal. NTM into quality press improvement safety, as markers outlet, of smart The very the standard recently evaluate system of life, electric MAC. enroll filter effective the is will the start X-step process: importance pilot patient, a
Data we safely treated NO date to that eradication. XXX-plus treat for from improve patients can on weeks parameters and patients current at XX of confidence rates multiple lives us with gives million, patients' per improve
at-home Based resources, significant a COPD XXXX. NTM patients on it we the with treated home. a exacerbations explore in a successful calendar study, we pathogen, severe chronic, our for the expect interim brought from of at-home underserved current in believe is program around potentially end report lung large the to our market infections very market. could door expectations, by in LungFit severe If very for we data any the opens with on And proper study which
these stellar. previously per weeks LungFit studies at was I of and between our have as where are would There microscopic, out like or two is in used the XX-day is no histopathology million, toxicology preclinical well. in to million and there In results treatment complement our the system words, the XX am observations. to our nitric in parts The the at-home with are used point in differences, macro there be versus complete, protocol and control. study. both with report rat will protocol study completed oxide were testing that no XXX been These that upcoming clinics that that pleased completed, NTM studies complete control. I our per dog other XXX mimicked were the rat XX-week results parts differences zero
we Before our through This I turn Doug activities, financials, it offering developments support anticipated completed of note at private $XX.X year public our gross proceeds. to in and that common million amounts to review the over and recently to important XXXX. stock, placement will fiscal least raising a it's
our and the We to XXXX the are in Day vision next New eager X months, Analyst X, XX our very with on excited at York. March for about I'm p.m. at you share outlook
display and with. attendance will in several to team of We Air the members Beyond commercial-ready our speak have systems
These pulmonary LungFit you KOLs truly is in-depth used. perspective involved, an and exciting We to will forward acute also and why have we on times bronchiolitis everyone look discussion next presenting month. hypertension, and their for are NTM with
over review. turn Doug Doug? will I call financial to that, With for the the
